Arnulf Stenzl, MD, medical director of the Department of Urology at the University of Tübingen in Germany, discusses future research efforts with enzalutamide (Xtandi) in prostate cancer.

Combination therapy is an exciting area of research in the prostate cancer paradigm, says Stenzl.

Moreover, the positive efficacy and safety data observed with enzalutamide may provide an opportunity for the agent to be combined with immunotherapy, Stenzl adds.

For example, checkpoint inhibitors may be an effective partner for the potent antiandrogen agent, Stenzl says.

Additionally, it is worth considering whether these combinations can be given perioperatively or concurrently with local therapy, concludes Stenzl.

Videos

Arnulf Stenzl, MD, discusses future research efforts with enzalutamide in prostate cancer.



Dr. Stenzl on Future Research With Enzalutamide in Prostate Cancer

Arnulf Stenzl, MD, medical director of the Department of Urology at the University of Tübingen in Germany, discusses the safety profile of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC).

, a posthoc analysis of the phase 3 ARCHES study showed that enzalutamide plus ADT led to an improvement in radiographic progression-free survival compared with ADT alone in men with mHSPC who had lymph node and/or bone metastatic spread.

According to Stenzl, the regimen was well tolerated and did not lead to a significant deterioration in patients’ quality of life.

Although all therapies have potential toxicities, brain-related adverse effects that have been associated with enzalutamide were not observed in the study, explains Stenzl. 

Previously, this combination was used in later-stage disease such as nonmetastatic or metastatic castration-resistant prostate cancer. However, these findings support the use of enzalutamide/ADT in mHSPC, concludes Stenzl.

Arnulf Stenzl, MD, discusses the safety profile of enzalutamide in combination with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.



Arnulf Stenzl, MD

Articles

Dr. Stenzl on Future Research With Enzalutamide in Prostate Cancer

Dr. Stenzl on the Safety Profile of Enzalutamide/ADT in mHSPC